Investor Presentaiton slide image

Investor Presentaiton

Revenue: Major Products in Japan (Bn JPY) FY2021 Q1 FY2022 Q1 YOY Results Results Lixiana anticoagulant 22.9 25.1 +2.2 Tarlige pain treatment 7.1 8.9 +1.8 Pralia treatment for osteoporosis/ inhibitor of the progression of bone erosion associated with rheumatoid arthritis 9.2 9.9 +0.7 Efient antiplatelet agent 4.1 4.9 +0.7 Tenelia type 2 diabetes mellitus treatment 6.4 5.6 -0.8 Vimpat anti-epileptic agent 4.5 5.3 +0.8 Ranmark treatment for bone complications caused by bone metastases from tumors 5.1 4.9 -0.2 Canalia type 2 diabetes mellitus treatment 4.3 4.1 -0.3 Loxonin anti-inflammatory analgesic 5.8 4.6 -1.2 anti-cancer agent Enhertu 2.2 2.4 +0.3 (HER2-directed antibody drug conjugate) Emgality prophylaxis of migraine attacks 0.9 1.4 +0.6 Daiichi-Sankyo 9
View entire presentation